Literature DB >> 30169342

Left ventricular function recovery after revascularization: comparative effects of percutaneous coronary intervention and coronary artery bypass grafting.

Janet M C Ngu1, Marc Ruel1, Louise Y Sun.   

Abstract

PURPOSE OF REVIEW: In 2013, heart failure with recovered ejection fraction (HFrecEF) was introduced as a new heart failure phenotype. This review provides an overview of HFrecEF and the comparative effects of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) on left ventricular ejection fraction (LVEF) recovery in patients with ischemic cardiomyopathy. RECENT
FINDINGS: There has been emerging data indicating that LV functional recovery is possible and HFrecEF is associated with improved survival and better quality of life. CABG may be associated with larger improvement in LVEF when compared with PCI. However, there is significant paucity of studies, which directly compare the impact of PCI and CABG on LVEF recovery in the setting of ischemic cardiomyopathy.
SUMMARY: LVEF recovery is emerging as an important outcome with demonstrated survival and quality-of-life benefits. Future randomized clinical trials comparing the impact of contemporary PCI and CABG on LVEF recovery are needed in patients with ischemic cardiomyopathy.

Entities:  

Mesh:

Year:  2018        PMID: 30169342     DOI: 10.1097/HCO.0000000000000566

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  3 in total

Review 1.  Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy.

Authors:  Chandra K Katikireddy; Arang Samim
Journal:  Clin Cardiol       Date:  2022-01-25       Impact factor: 2.882

2.  Evaluation of Left Ventricular Myocardial Work Performance in Patients Undergoing On-Pump and Off-Pump Coronary Artery Bypass Surgery.

Authors:  Konstantina Spetsotaki; Rashad Zayat; Srinath Donuru; Ruediger Autschbach; Heike Schnoering; Nima Hatam
Journal:  Ann Thorac Cardiovasc Surg       Date:  2020-09-07       Impact factor: 1.520

3.  Ginsenoside Rg2 alleviates myocardial fibrosis by regulating TGF-β1/Smad signalling pathway.

Authors:  Quanwei Wang; Wenwen Fu; Xiaofeng Yu; Huali Xu; Dayun Sui; Yeling Wang
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.